ATIM-33 - Interim Results of a Phase II Multi-center Study of Oncolytic Adenovirus DNX-2401 with Pembrolizumab for Recurrent Glioblastoma; CAPTIVE Study (KEYNOTE-192)

Sunday, November 24

8:55 AM - 9:05 AM

Location: Grand Canyon 1-6

Author(s)

Timothy Cloughesy

Professor
University of California Los Angeles
HC

Howard Colman

Huntsman Cancer Institute, University of Utah
MD

Mariza Daras

Memorial Sloan Kettering Cancer Center
MG

Morris Groves

U.S. Oncology
Simon Khagi

Assistant Professor
University of North Caroline School of Medicine
Priya Kumthekar

Assistant Professor
Northwestern University
Frederick Lang

Chairman, Department of Neurosurgery
MD Anderson Cancer Center
Farshad Nassiri

MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
SO

Shirley Ong

University of Arkansas for Medical Sciences
Rohan Ramakrishna

Associate Professor Of Neurological Surgery Co-Director, Rhodes Center for Glioblastoma Director, Brain Metastases Program
NewYork Presbyterian- Weill Cornell Medical Center
AS

Adam Sonabend

Northwestern University, Feinberg School of Medicine
Michael Vogelbaum

Program Leader and Chief of Neurosurgery
Moffitt Cancer Center
Gelareh Zadeh

Medical Director, Krembil Brain Institute, UHN Neurosurgeon, Professor of Surgery, University of Toronto Senior Scientist, Princess Margaret Cancer Research Institute
University Health Network
LA

Laura Agensky

DNAtrix, Inc.
CB

Carin Bidwell

DNAtrix, Inc.
BW

Barry Watkins

DNAtrix, Inc.
FT

Frank Tufaro

DNAtrix, Inc.
JP

Joanna Peterkin

DNAtrix, Inc.